Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide does not ruin your metabolism. Clinical evidence shows it reduces appetite and body weight, but the metabolic changes it causes — including some reduction in resting energy expenditure — are consistent with losing weight itself, not a drug-specific penalty. Understanding what actually happens to your metabolism on semaglutide helps set realistic expectations. These are prescription-only medicines, and a clinician reviews whether they are appropriate for you before any treatment begins. The questions below trace what the evidence shows, step by step.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is a GLP-1 receptor agonist, it mimics a gut hormone that signals fullness to the brain, slows how quickly your stomach empties, and reduces appetite. Sold in the UK for weight management as Wegovy, it is a once-weekly injection titrated gradually from a low starting dose. You can read a fuller overview of how the medicine works on the semaglutide treatment page.
The appetite effect is central to understanding metabolism. Semaglutide does not directly instruct your cells to burn less energy. What it does is change how much you want to eat. Calorie intake falls, and (because your body is running on less fuel) total energy expenditure naturally adjusts downward. That adjustment is proportional to the weight you lose, not a special feature of the drug itself.
Clinical trial data, including the STEP 1 trial published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4mg dose. Participants maintained substantial losses for as long as they continued treatment alongside lifestyle changes. That kind of result does not fit the picture of a medicine destroying the body's capacity to burn energy.
Here is the part worth taking seriously. When anyone loses a significant amount of weight (by any means) resting energy expenditure (the calories your body burns at rest) falls. This happens because a smaller body simply requires less energy to maintain itself. It is sometimes called adaptive thermogenesis, and it is well-documented in obesity research going back decades.
Semaglutide is no exception. People losing weight on it will likely find their maintenance calorie level is lower than it was before treatment. The NHS patient information for semaglutide notes this broader context in its guidance on weight management medicines, and NHS England's guidance on weight management injections emphasises the importance of diet and physical activity alongside treatment for exactly this reason.
What the evidence does not show is that semaglutide causes a metabolic slowdown beyond what weight loss alone would produce. The medicine is not uniquely harmful to metabolic rate. Framing ordinary weight-loss physiology as the drug "ruining" your metabolism misrepresents the mechanism.
A quick check you can do in under a minute: pull up the NHS Better Health calorie guidance and compare a rough estimate of your current intake against your pre-treatment baseline. If the gap feels alarming, it is worth raising with your prescriber at the next review, that conversation is exactly what ongoing clinical oversight is for.
The real risk worth discussing is muscle loss. When calorie intake drops sharply, the body can draw on lean tissue as well as fat for fuel. Muscle is metabolically active (it burns more energy at rest than fat tissue) so losing a meaningful amount of it would genuinely lower your resting metabolic rate over time.
This is not inevitable, and it is addressable. Adequate protein intake and regular resistance exercise during treatment are the two most evidence-backed ways to preserve muscle mass while losing weight. This is not advice unique to semaglutide; it applies to any significant calorie deficit. Our weight-loss treatment overview covers the lifestyle elements that support treatment.
For a deeper look at how semaglutide specifically interacts with the metabolic picture, the semaglutide and metabolism page explores the science in more detail, and if you are curious about whether Wegovy affects your metabolic rate specifically, the page covering how Wegovy affects metabolism walks through what the current evidence shows, alongside further context on whether the medicine can actively help metabolic function at does Wegovy help metabolism.
The concern most people are really asking about is this: "If I stop taking semaglutide, will my metabolism be wrecked?" It is a fair question. The clinical evidence does show that weight tends to return after stopping treatment if the lifestyle changes that accompanied it are not maintained, the STEP 1 trial extension data demonstrated this clearly.
Weight regain after stopping is not the same as permanent metabolic damage. The body is re-gaining weight, and energy expenditure is adjusting back upward accordingly. It is a frustrating biological reality, not evidence that the drug has broken something irreparably. Research exploring whether semaglutide produces any metabolic change beyond what weight loss explains (including questions about whether it might affect metabolism in beneficial ways) is discussed on the does semaglutide change your metabolism page.
If you are weighing up the options and want to understand cost alongside the clinical picture, the Wegovy cost context page sets out what private treatment typically involves in the UK. And if your questions have moved from the science to what the next step looks like, our prescribers are available through a free consultation, reviewed by a real clinician the same day you submit it, not by software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.